Feedback
Crohn Disease Prognostic Panel
2001613
Ordering Recommendation

Aid in the diagnosis and prognostication of Crohn disease.

Mnemonic
CROHN PAN
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Performed
Tue
Reported
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Serum separator tube (SST). 
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Plasma, other body fluids, grossly icteric, heat-inactivated, grossly hemolyzed, severely lipemic, or contaminated specimens. 
Remarks
 
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
(avoid repeated freeze/thaw cycles) 
Reference Interval
Available Separately
Components
Reference Interval
NoSaccharomyces cerevisiae Antibody (gASCA), IgG0-44 Units: Negative
45-50 Units: Equivocal
51 Units or greater: Positive
NoLaminaribioside Carbohydrate Antibody (ALCA), IgG0-54 Units: Negative
55-60 Units: Equivocal
61 Units or greater: Positive
NoMannobioside Carbohydrate Antibody (AMCA), IgG0-89 Units: Negative
90-100 Units: Equivocal
101 Units or greater: Positive
NoChitobioside Carbohydrate Antibody (ACCA), IgA0-79 Units: Negative
80-90 Units: Equivocal
91 Units or greater: Positive

Interpretive Data
Anti-glycan serologic markers may serve as an aid in the diagnosis of Crohn disease (CD) and an indicator of disease prognosis. Anti-saccharomyces cerevisiae antibody (gASCA) has the highest diagnostic value and anti-chitobioside carbohydrate antibody (ACCA) has the highest association with more-aggressive disease. Both ACCA and gASCA are associated equally with the need for surgery. When found in combination, these markers have the best diagnostic potential. A combination of two or more of the four anti-glycan markers have a significant association with complications and the need for surgery than any single marker alone. A negative result does not rule out CD.

Compliance Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.

Note
CPT Code(s)
86671; 83516 x3
Components
Component Test Code*Component Chart NameLOINC
2001609Saccharomyces cerevisiae Ab (gASCA), IgG47321-5
2001610Mannobioside Carbohydrate Ab (AMCA), IgG53597-1
2001611Laminaribioside Carbohydrate Ab ALCA IgG53596-3
2001612Chitobioside Carbohydrate Ab (ACCA), IgA53594-8
2013334Crohn Disease Prognostic Pan Interp.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Chitobioside Carbohydrate Antibody (ACCA), IgA
  • Glycan Antibodies
  • IBD Prognostic Panel
  • IBDX
  • Inflammatory Bowel Disease Prognostic Panel
  • Laminaribioside Carbohydrate Antibody (ALCA), IgG
  • Saccharomyces cerevisiae Antibody (gASCA), IgG